TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Duration of bronchodilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: first heart failure hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: 5-year recurrence rate
Endpoint domain: Mortality/survival
Primary endpoint: Mean rating for item quality
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Responder status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Future symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary safety composite end point at 30 days
Endpoint domain: Adverse events/effects
Primary endpoint: Primary effectiveness composite end point at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Moderate or severe paravalvular leak at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: plasma creatine kinase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: tumor necrosis factor (TNF)‐α concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: plasma total antioxidant activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ejaculation latency time (ELT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severe retinopathy of prematurity
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in spasms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spasm free status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Moderate-to-severe MR recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Dental caries incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mutans streptococci levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in walking to work
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrence rate at 3 months
Endpoint domain: Mortality/survival
Primary endpoint: 1 year recurrence rate
Endpoint domain: Mortality/survival
Primary endpoint: 2 years recurrence rate
Endpoint domain: Mortality/survival
Primary endpoint: Number of acute attacks of gouty arthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional scores on the American Orthopaedic Foot and Ankle Society Ankle‐Hindfoot Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvements in verbal and spatial memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: number of embryos
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cancer recurrence rate
Endpoint domain: Mortality/survival
Primary endpoint: peak estradiol (E2) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Postoperative intraocular pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: markers of bone turnover
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Complete obliteration of the aneurysm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residual neck of the aneurysm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residual aneurysm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alcohol-related negative consequences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PONV rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: life-time binge drinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OLP (Oxygenation Level Pressure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ventilation scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax for hydrocodone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax for APAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of metabolic acidaemia at birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ankle joint function (Karlsson score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bronchospasm episodes after influenza vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Mean concentrations of levodopa-carbidopa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and type of adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative mortality by 90 days
Endpoint domain: Mortality/survival
Primary endpoint: Oral cancer development rate
Endpoint domain: Mortality/survival
Primary endpoint: Diagnosis rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cost per diagnosis
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mortality Rate (MR)
Endpoint domain: Mortality/survival
Primary endpoint: Survival rate after aging cycles
Endpoint domain: Mortality/survival
Primary endpoint: sNOX2-dp levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum isoprostanes levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CK-18 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular Surface Disease Index (OSDI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ocular symptoms subscale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time in the postoperative anesthesia care unit (PACU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercise-induced ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ischemia on ambulatory electrocardiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Follow-up rate for infants with sickle cell trait
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Retention of information by parents
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Morphine consumption in the first 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative sufentanil consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to chest tube removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Detection of high-risk prostate cancer (PrCA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Composite of death, myocardial infarction, or cerebrovascular accident
Endpoint domain: Mortality/survival
Primary endpoint: Change in CBFV due to respiratory manoeuvre
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LVM(bsa) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain over a 24-h period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of cardiac arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: major morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: asthma exacerbations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: emergency department visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: hospitalizations for asthma
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Improvement in PRSS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptomatic improvement in itching (pruritus scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chronic neuropathic pain incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in the area of Barrett's oesophagus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach > 0.5 x 10(9)/L granulocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QALY difference
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Adjusted difference in costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Fugl-Meyer Assessment of the Upper Extremity (FMA-UE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brunnstrom stages
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Ashworth Scale (MAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delayed onset muscle soreness (DOMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Identification of Risks
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean energy intake at lunchtime
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical course of EDSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: NRS (Numerical Rating Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Secondary effects due to interferon
Endpoint domain: Adverse events/effects
Primary endpoint: Acute urinary retention events
Endpoint domain: Adverse events/effects
Primary endpoint: Need for surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Exacerbation risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma [glucose] levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma soluble vascular cell adhesion molecule 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Neutropenia grade 3 and 4
Endpoint domain: Adverse events/effects
Primary endpoint: retinal arteriolar contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Seizure occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Blood pressure response to ACE inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: KWST score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FIRS and VFSS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment-related costs per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: sitagliptin maximum plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma concentration‐time curve from zero to infinity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fraction of sitagliptin excreted unchanged in the urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: sella-nasion-mandibular plane angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mandibular incisor-mandibular plane angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maxillary incisor-nasion-A-point angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemolysis risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Hepatic venous pressure gradient reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean arterial pressure reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of arterial hypotension
Endpoint domain: Adverse events/effects
Primary endpoint: weekly subject ratings of hair pulling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weekly subject ratings of the urge to pull hair
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weekly assessments of the number of hair‐pulling episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: estimated amount of hair pulled per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: superiority of sacubitril/valsartan over enalapril
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: steady-state trough concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: standardized vibration‐induced SOST index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: resting myoelectrical activity of adductor muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lgCFU/ml of black‐pigmented bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lgCFU/ml of Fn
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: detection rates of black‐pigmented bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Alcohol Withdrawal Scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respiration reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in the risk of cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in the incidence of new cases of hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Early mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: Rate of virus decay in lymph tissue (LT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: major complications
Endpoint domain: Adverse events/effects
Primary endpoint: tympanic temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: thrombocytopaenia incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Response rate (CR + PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Serum concentrations of triglyceride
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum concentrations of very‐low‐density lipoprotein triglyceride
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cell death by TUNEL staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lipid content by oil red O staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Collagen content by Sirius red staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in pain VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in passive ROM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in Constant score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major bleeding rate
Endpoint domain: Adverse events/effects
Primary endpoint: gastric half emptying time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: gastric secretion volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Five-year cumulative probability of survival
Endpoint domain: Mortality/survival
Primary endpoint: Confidence in discussing STI screening
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Confidence in convincing partners to use condoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: operative mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: development of postoperative encephalopathy
Endpoint domain: Adverse events/effects
Primary endpoint: Differences in rotation and translation of bony segmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Reduction of overall psychotic and negative symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adverse events and extrapyramidal symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Normalization rate of blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge, attitudes and behaviours related to puberty and health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction of elastance (K(LV))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in NYHA class
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of brain natriuretic peptide (BNP) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Medical errors of moderate or greater clinical significance
Endpoint domain: Adverse events/effects
Primary endpoint: Average duration of RSMI encounters
Endpoint domain: Resource use
Primary endpoint: Mean time to achieve maximum vision postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean postoperative corneal thickness increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time to return to preoperative pachymetry values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abstinence at the end of the medication phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: family well-being
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Lesion CR rates at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient CR rates at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rating of cosmetic outcome
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Right amygdala activity to facial stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: next-day spasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epworth somnolence score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carrying angle restoration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flynn's overall rating
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cumulative discontinuation due to GI adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative use of medication to treat GI symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: mTICI grade of 2 to 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 90-day modified Rankin Scale score of 0 to 2
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Occurrence of hypotension
Endpoint domain: Adverse events/effects
Primary endpoint: Amount of ephedrine required
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in DAS28(CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ultrasound (US) endpoints for MCPJ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Harris scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: necrosis area of femoral head
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of nausea and vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Energy intake at lunchtime
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Relative energy intake postexercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: reduction in intrusion occurrence
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean maximum percentage fall in FEV(1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of patients protected against EIB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: single twitch torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: maximal voluntary torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: synergistic voluntary muscle activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: VAS score of low back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: accuracy of pedicle screw
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes